Liver Cirrhosis Treatment Market Size, Share, Growth Analysis, By Treatment Modality(Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents), By Disease(Hepatitis, Non-alcoholic Fatty Liver Disease, Alcohol-induced, and Liver Cancer), By Region - Industry Forecast 2024-2031

Q: What is the global market size of Liver Cirrhosis Treatment Market?

Global Liver Cirrhosis Treatment Market size was valued at USD 16.69 Billion in 2022 and is poised to grow from USD 17.76 Billion in 2023 to USD 29.21 Billion by 2031, growing at a CAGR of 6.42% in the forecast period (2024-2031).

Q: Who are the key vendors in the Global Liver Cirrhosis Treatment Market?

The competitive environment of the Global Liver Cirrhosis Treatment Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. The liver cirrhosis treatment market is fragmented, with several key players. In terms of market share, the market is currently dominated by a few major players. The companies currently dominating the market include Abbott Laboratories, Gilead Sciences, Novartis AG, Sanofi, Astellas Pharma, Inc. and others. 'Pfizer, Inc.', 'Merck & Co., Inc.', 'Novartis AG', 'Takeda Pharmaceuticals Company Ltd.', 'Zydus Pharmaceuticals, Inc.', 'Gilead Science, Inc.', 'Sanofi S.A.', 'AstraZeneca plc', 'GSK plc', 'AbbVie Inc.', 'Abbott Laboratories', 'Astellas Pharma Inc.', 'Bristol Myers Squibb', 'Eli Lilly and Company', 'F. Hoffman-LA Roche', 'Emergent BioSolutions (Cangene bioPharma)', 'Gilead Sciences, Inc.,', 'Merck & Co., Inc. (Merck Sharp & Dohme Corp.)', 'Viatris Inc.'

Q: What is the key market trend for Global Liver Cirrhosis Treatment Market?

Rising Research and Development Efforts Increasing R&D efforts to develop new therapies and therapeutic targets for liver disease, increasing services and funding for prevention, diagnosis and treatment of liver disease, increasing liver disease awareness, if needed the need for early diagnosis and healthcare costs. Increasing aging population, increasing awareness, improving healthcare infrastructure, increasing disposable income in emerging markets and increasing advancement in surgical procedures, procedures not taken more penetration and radiology interventions further support the growth of the market.

Report ID: SQMIG35A2887 | Region: Global | Published Date: May, 2024
Pages: 218 | Tables: 66 | Figures: 74

Liver Cirrhosis Treatment Market News

On January 31, 2022, Madrigal Pharmaceuticals saw an increase in premarket activity as the company delivered encouraging top-line data from the resmetirom study in non-alcoholic fatty liver disease.

On September 30, 2021, Livmarly, Mirum’s minimally absorbed ileal bile acid transport (iBAT) inhibitor, received FDA approval. Emerging antibiotics are the first-line treatment for the disease, which affects 2,000–2,500 young people in the United States.

January 2023: Takeda and Arrowhead Pharmaceuticals Inc. announced superior results of the Phase 2 SEQUOIA clinical trial of investigational fajirsiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATD-LD).

Liver Cirrhosis Treatment Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Liver Cirrhosis Treatment Market size was valued at USD 16.69 Billion in 2022 and is poised to grow from USD 17.76 Billion in 2023 to USD 29.21 Billion by 2031, growing at a CAGR of 6.42% in the forecast period (2024-2031).

The competitive environment of the Liver Cirrhosis Treatment Market is dynamic and characterized by the presence of a mix of well-established brands, emerging players, and niche producers. Innovation is a key competitive factor. The liver cirrhosis treatment market is fragmented, with several key players. In terms of market share, the market is currently dominated by a few major players. The companies currently dominating the market include Abbott Laboratories, Gilead Sciences, Novartis AG, Sanofi, Astellas Pharma, Inc. and others. 'Pfizer, Inc.', 'Merck & Co., Inc.', 'Novartis AG', 'Takeda Pharmaceuticals Company Ltd.', 'Zydus Pharmaceuticals, Inc.', 'Gilead Science, Inc.', 'Sanofi S.A.', 'AstraZeneca plc', 'GSK plc', 'AbbVie Inc.', 'Abbott Laboratories', 'Astellas Pharma Inc.', 'Bristol Myers Squibb', 'Eli Lilly and Company', 'F. Hoffman-LA Roche', 'Emergent BioSolutions (Cangene bioPharma)', 'Gilead Sciences, Inc.,', 'Merck & Co., Inc. (Merck Sharp & Dohme Corp.)', 'Viatris Inc.'

Liver disease is still very common worldwide. Due to sedentary lifestyle, inactivity and especially poor diet, many people are suffering from liver disease. The aging population is getting older, and autoimmune diseases such as hepatitis and non-alcoholic fatty liver are on the rise. We can also attribute the significant increase in cases to alcohol consumption greater than. Increasing availability of therapies for liver diseases will drive the market for treatment of liver diseases. In response to increased demand for hepatitis treatment, healthcare organizations funded the development of new drugs, devices, and treatment options, supported by biotechnology and research institutes around the world greatly led to the development of new drugs for the treatment of liver disease. Due to the growth and development, the market for treatment of liver diseases will be highly competitive and prosperous. This is expected to open lucrative opportunities for market participants and accelerate market growth.

Rising Research and Development Efforts: Increasing R&D efforts to develop new therapies and therapeutic targets for liver disease, increasing services and funding for prevention, diagnosis and treatment of liver disease, increasing liver disease awareness, if needed the need for early diagnosis and healthcare costs. Increasing aging population, increasing awareness, improving healthcare infrastructure, increasing disposable income in emerging markets and increasing advancement in surgical procedures, procedures not taken more penetration and radiology interventions further support the growth of the market.

The largest regional market. cirrhosis of the liver is common in the United States. In the U.S. saw 88,000 deaths from alcohol-related liver disease and hepatitis. Additionally, the health care system in the U.S. has 88,000 deaths from alcohol-related liver disease is also growing, contributing to the growth of the liver cirrhosis treatment market. Furthermore, Pfizer Inc. has a strong presence in the market.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Liver Cirrhosis Treatment Market Size, Share, Growth Analysis, By Treatment Modality(Antiviral, Vaccines, Chemotherapy, Immunosuppressive Agents), By Disease(Hepatitis, Non-alcoholic Fatty Liver Disease, Alcohol-induced, and Liver Cancer), By Region - Industry Forecast 2024-2031

Liver Cirrhosis Treatment Market News

Liver Cirrhosis Treatment Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Liver Cirrhosis Treatment Market?

Who are the key vendors in the Liver Cirrhosis Treatment Market?

What is the key driver of Liver Cirrhosis Treatment Market?

What is the key market trend for Liver Cirrhosis Treatment Market?

Which region accounted for the largest share in Liver Cirrhosis Treatment Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300